Review



psav calculations  (Johns Hopkins HealthCare)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Johns Hopkins HealthCare psav calculations
    Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
    Psav Calculations, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/psav+calculations/pmc04711358-194-16-19
    Average 90 stars, based on 1 article reviews
    psav calculations - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer"

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    Journal: The Journal of urology

    doi: 10.1016/j.juro.2013.09.029

    Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.
    Figure Legend Snippet: Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Techniques Used:

    PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.
    Figure Legend Snippet: PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Techniques Used:

    Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012
    Figure Legend Snippet: Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012

    Techniques Used:

    Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.
    Figure Legend Snippet: Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.

    Techniques Used:

    ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.
    Figure Legend Snippet: ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.

    Techniques Used:

    Related Articles

    other:

    Article Title: Point: Impact of prostate-specific antigen velocity on management decisions and recommendations.
    Article Snippet: For example, in the Johns Hopkins active surveillance program, PSAV (and PSA doubling time) were not reliably indicative of disease reclassification on biopsy,17 whereas other programs have reported conflicting results.18 Currently, a lack of consensus exists regarding the use of PSA kinetics to indicate progressive disease in active surveillance programs.19 In the systematic review by Vickers et al,16 combining disparate outcomes such as initial biopsy results and progression on active surveillance in a systematic review may have affected the results.

    Article Title: Study supports PSA velocity risk count.
    Article Snippet: PSAV risk count was first developed and researched by H. Ballentine Carter, M.D., professor of urology and professor of oncology at Johns Hopkins University School of Medicine in Baltimore.



    Similar Products

    dna fragments mutation wspf psyr psav deletion mwsr (pspto_4631  (Thermo Fisher)
    90
    Thermo Fisher dna fragments mutation wspf psyr psav deletion mwsr (pspto_4631
    Dna Fragments Mutation Wspf Psyr Psav Deletion Mwsr (Pspto 4631, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/pm39657800-228-8-24
    Average 90 stars, based on 1 article reviews
    dna fragments mutation wspf psyr psav deletion mwsr (pspto_4631 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    motorized elevator psav-100-zf  (Zolix Instruments Co Ltd)
    90
    Zolix Instruments Co Ltd motorized elevator psav-100-zf
    Motorized Elevator Psav 100 Zf, supplied by Zolix Instruments Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/motorized+elevator+psav+100+zf/10__1109_slash_tbme__2017__2758905-89-44-46
    Average 90 stars, based on 1 article reviews
    motorized elevator psav-100-zf - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    psav calculations  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare psav calculations
    Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
    Psav Calculations, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/psav+calculations/pmc04711358-194-16-19
    Average 90 stars, based on 1 article reviews
    psav calculations - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    anti-psav capsid monoclonal antibody  (Santa Cruz Biotechnology)
    90
    Santa Cruz Biotechnology anti-psav capsid monoclonal antibody
    Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
    Anti Psav Capsid Monoclonal Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/anti+psav+capsid+monoclonal+antibody/pm24901849-199-15-28
    Average 90 stars, based on 1 article reviews
    anti-psav capsid monoclonal antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    psav  (Wolters Kluwer Health)
    90
    Wolters Kluwer Health psav
    Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
    Psav, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/psav/10__1097_slash_mou__0000000000000050-65-26-3
    Average 90 stars, based on 1 article reviews
    psav - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    psav  (Johns Hopkins HealthCare)
    90
    Johns Hopkins HealthCare psav
    Study design shows timing of biopsies, PSA testing and periods for successive <t>PSAV</t> calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in <t>Johns</t> <t>Hopkins</t> AS Program from 1995 to 2012.
    Psav, supplied by Johns Hopkins HealthCare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/psav/psav/pm23486454-38-9-4
    Average 90 stars, based on 1 article reviews
    psav - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Journal: The Journal of urology

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    doi: 10.1016/j.juro.2013.09.029

    Figure Lengend Snippet: Study design shows timing of biopsies, PSA testing and periods for successive PSAV calculations 1 to 3 (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

    Techniques:

    PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Journal: The Journal of urology

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    doi: 10.1016/j.juro.2013.09.029

    Figure Lengend Snippet: PSAV in men with 3 serial PSAV measurements (PSAV1, PSAV2 and PSAV3, respectively) in Johns Hopkins AS Program from 1995 to 2012.

    Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

    Techniques:

    Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012

    Journal: The Journal of urology

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    doi: 10.1016/j.juro.2013.09.029

    Figure Lengend Snippet: Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012

    Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

    Techniques:

    Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.

    Journal: The Journal of urology

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    doi: 10.1016/j.juro.2013.09.029

    Figure Lengend Snippet: Cumulative incidence of unfavorable biopsies by RC during followup in men with 3 serial PSAV calculations in Johns Hopkins AS Program from 1995 to 2012.

    Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

    Techniques:

    ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.

    Journal: The Journal of urology

    Article Title: Prostate Specific Antigen Velocity Risk Count Predicts Biopsy Reclassification for Men with Very Low Risk Prostate Cancer

    doi: 10.1016/j.juro.2013.09.029

    Figure Lengend Snippet: ROC analysis of base logistic regression model vs models with addition of overall PSAV or PSAV RC for outcomes of biopsy reclassification by any criteria (A) and specifically Gleason score reclassification (GSR) (B) in Johns Hopkins AS Program from 1995 to 2012.

    Article Snippet: ‡ Chi-square p = 0.017. caption a8 Biopsy reclassification associations with RC in men with 3 PSAV calculations in Johns Hopkins AS Program from 1995 to 2012 Logistic regression models were also adjusted for period duration.

    Techniques: